Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06759077 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life

StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Dec 28, 2024 to Mar 28, 2026 Show 7 more changesShow less
    • Start date: Dec 28, 2024 to Feb 1, 2025
    • Primary endpoints: details revised at 1 of 1 entry
    • Trial completed
    • Study completion date changed from estimate of Dec 28, 2025 to Apr 28, 2026
    • Eligibility criteria expanded, about 9 words
    • Study description revised
    • Publications: details revised at 7 of 7 entries
  2. Study description shortened, about 5 wordsv3
  3. Secondary endpoints: details revised at 1 of 1 entry
    • Study description shortened, about 22 words
    • Site details revised
    • Eligibility criteria shortened, about 1 word
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
If this study has a cardio protective effect it will affect the mortality and morbidity of advanced CKD patients and improve their quality of life
Trial Details
NCT Number NCT06759077
Lead Sponsor Al-Azhar University
Conditions
(from sponsor)		 Kidney Diseases
Related terms Kidney Diseases
Enrollment 126 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov